Method for Preserving Neural Tissue
An object of the present invention is to provide a method for preserving neural tissue for several hours to several weeks without freezing, a preservation solution therefor, a transport method for neural tissue in accordance with the method and using the preservation solution, and a composition for transplantation. The preservation method for neural tissue, comprising preserving neural tissue in a preservation solution having a potassium ion concentration of more than 0 mM and less than 115 mM at a preservation temperature of 8° C. to 30° C. The preservation solution having a potassium ion concentration of more than 0 mM and less than 115 mM, for preserving neural tissue derived from pluripotent stem cells at a preservation temperature of 8° C. to 30° C.
1 . A preservation method for neural tissue, comprising preserving neural tissue in a preservation solution having a potassium ion concentration of more than 0 mM and less than 115 mM at a preservation temperature of 8° C. to 30° C.
2 . The preservation method according to claim 1 , wherein the preservation temperature is 12° C. to 22° C.
3 . The preservation method according to claim 1 , wherein the neural tissue is derived from a human.
4 . The preservation method according to claim 1 , wherein the neural tissue is a tissue derived from pluripotent stem cells.
5 . The preservation method according to claim 1 , wherein the neural tissue is a tissue to be subjected to transplantation.
6 . The preservation method according to claim 1 , wherein the neural tissue is a cell aggregate having a layer structure.
7 . The preservation method according to claim 6 , wherein the neural tissue is a cell aggregate having a neuroepithelial structure.
8 . The preservation method according to claim 7 , wherein the neuroepithelial structure is a continuous epithelium structure present on a surface of the cell aggregate and/or a rosette structure present on a surface of or inside the cell aggregate.
9 . The preservation method according to claim 1 , wherein the neural tissue includes one or more neural tissues selected from the group consisting of forebrain tissue, midbrain tissue and retinal tissue.
10 . The preservation method according to claim 1 , for preservation for a period of 14 days or less.
11 . The preservation method according to claim 1 , for preservation for a period of 5 days or less.
12 . The preservation method according to claim 1 , wherein the preservation solution is an aqueous solution containing a buffering agent and having a buffering action to control pH within the range of 6.0 to 8.6.
13 . The preservation method according to claim 1 , wherein the preservation solution is the aqueous solution further containing a glycosaminoglycan.
14 . The preservation method according to claim 13 , wherein the concentration of the glycosaminoglycan is 0.1% (w/v) or more and 10% (w/v) or less.
15 . The preservation method according to claim 13 , wherein the glycosaminoglycan includes one or more glycosaminoglycans selected from the group consisting of chondroitin sulfate and hyaluronic acid.
16 . A preservation solution having a potassium ion concentration of more than 0 mM and less than 115 mM, for preserving neural tissue derived from pluripotent stem cells at a preservation temperature of 8° C. to 30° C.
17 . The preservation solution according to claim 16 , wherein the preservation temperature is 12° C. to 22° C.
18 . The preservation solution according to claim 16 , wherein the neural tissue is a cell aggregate having a layer structure.
19 . The preservation solution according to claim 18 , wherein the neural tissue is a cell aggregate having a neuroepithelial structure.
20 . The preservation solution according to claim 19 , wherein the neuroepithelial structure is a continuous epithelium structure present on a surface of the cell aggregate and/or a rosette structure present on a surface of or inside the cell aggregate.
21 . A transport method for neural tissue, comprising transporting neural tissue in a preservation solution having a potassium ion concentration of more than 0 mM and less than 115 mM at a preservation temperature of 8° C. to 30° C.
22 . The transport method according to claim 21 , wherein the preservation temperature is 12° C. to 22° C.
23 . The transport method according to claim 21 , wherein the neural tissue is a tissue derived from human pluripotent stem cells.
24 . The transport method according to claim 21 , wherein the neural tissue is a tissue to be subjected to transplantation.
25 . The transport method according to claim 21 , wherein the neural tissue is a cell aggregate having a layer structure.
26 . The transport method according to claim 25 , wherein the neural tissue is a cell aggregate having a neuroepithelial structure.
27 . The transport method according to claim 26 , wherein the neuroepithelial structure is a continuous epithelium structure present on a surface of the cell aggregate and/or a rosette structure present on a surface of or inside the cell aggregate.
28 . The transport method according to claim 21 , wherein the neural tissue is one or more neural tissues selected from the group consisting of forebrain tissue, midbrain tissue and retinal tissue
29 . A composition for transplantation at a temperature of 12° C. to 22° C., comprising an aqueous solution having a potassium ion concentration of more than 0 mM and less than 115 mM and pH controlled by a buffering agent within the range of 6.0 to 8.6 and a human neural tissue derived from pluripotent stem cells.
30 . The composition according to claim 29 , wherein the neural tissue is a cell aggregate having a layer-like neuroepithelial structure.
31 . The composition according to claim 30 , wherein the neuroepithelial structure is a continuous epithelium structure present on a surface of the cell aggregate and/or a rosette structure present on a surface of or inside the cell aggregate.
32 . The composition according to claim 29 , wherein the neural tissue includes one or more neural tissues selected from the group consisting of forebrain tissue, midbrain tissue and retinal tissue.
33 . The composition according to claim 29 , wherein the aqueous solution is the aqueous solution further containing a glycosaminoglycan of 0.1% (w/v) or more and 10% (w/v) or less.